(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...
Nov 30, 2015
0
1
Combining five existing drugs can keep a highly aggressive type of bone marrow cancer at bay for longer, an innovative trial has shown.
Jun 23, 2023
0
20
(Medical Xpress)—Before all the excitement about embryonic stem cells, doctors were using hematopoetic – that is, blood-forming—stem cells. Hematopoetic stem cells can replenish all the types of cells in the blood, ...
Jan 4, 2013
0
0
A new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) provides evidence that genetically modifying ...
May 12, 2014
0
0
Scientists from A*STAR's Bioprocessing Technology Institute (BTI) have uncovered the crucial role of two signalling molecules, DOK3 and SHP1, in the development and production of plasma cells. These discoveries, published ...
Sep 1, 2014
0
0
(Medical Xpress) -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej ...
Dec 8, 2011
0
0
(HealthDay)—A two-pronged immune-boosting drug could provide new hope for people stricken with multiple myeloma, a cancer of the blood and bone marrow, according to clinical trial findings.
Jun 2, 2015
0
20
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow ...
Feb 5, 2016
0
6
Multiple myeloma is a cancer of the white blood cells, and patients diagnosed with this disease commonly die within five years. Clinicians often treat multiple myeloma with the drug thalidomide and structurally similar drugs ...
Sep 21, 2020
0
65
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or ...
Jun 5, 2017
0
2
